Skip to navigation Skip to content

Hodgkin lymphoma (HL) Program in Pharmaceutical Benefits Scheme (PBS) 012-18042700

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma (HL) who have failed autologous stem cell transplant (ASCT) or are ASCT naïve. It also outlines details of PBS-subsidised brentuximab vedotin for patients with initial Stage III or IV CD30 positive Hodgkin lymphoma.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Relapsed or refractory Hodgkin lymphoma (HL) quick reference

Table 1

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

Telephone

Electronic

S100:

brentuximab vedotin

No

OPA

Not specified

Yes

Continuing

Telephone

Electronic

S100:

brentuximab vedotin

No

OPA

Not specified

Yes

Initial

Streamlined

S100:

pembrolizumab (General schedule)

No

N/A

Not specified

N/A

Continuing

Streamlined

S100:

pembrolizumab (General schedule)

No

N/A

Not specified

N/A

Stage III or IV CD30 positive Hodgkin lymphoma (HL) quick reference

Table 2

Restriction

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial / Continuing (no treatment phase)

Telephone

Electronic

S100:

brentuximab vedotin

No

OPA

Not specified

Yes